OAM
CRSP icon

Oxford Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Oxford Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-27,306
Closed -$1.66M – 460
2019
Q4 		$1.66M Buy
27,306
+13,346
+96% +$729K 0.05% 534
2019
Q3 		$572K Buy
+13,960
New +$667K 0.01% 1211

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oxford Asset Management's CRSP Position: Q1 2020 in Review

Oxford Asset Management sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 27,306 shares — an estimated $1.66M sold.

Oxford Asset Management first reported a position in CRSP in Q3 2019 and held it in 2 quarters. The position peaked at $1.66M in Q4 2019. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

  • Oxford Asset Management reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 27,306 CRISPR Therapeutics shares in Q1 2020, an estimated $1.66M.
  • Oxford Asset Management first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 2 quarters.
  • Oxford Asset Management's CRISPR Therapeutics position peaked at $1.66M in Q4 2019.
  • 257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.